SQLite Web: event_store.db

Update row sig_2a20c7b4f30c in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/biotech-stock-best-chance-make-fortune-healthcare","as_of":"2026-04-10T17:21:18.772571+00:00","canonical_url":"https://www.fool.com/investing/2026/04/10/is-this-biotech-stock-the-best-chance-to-make-a-fo/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/biotech-stock-best-chance-make-fortune-healthcare","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_399acdfd3ab0e7e7","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/10/is-this-biotech-stock-the-best-chance-to-make-a-fo/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T19:21:02.580609+00:00","extraction_method":"heuristic","fetched_description":"Key PointsIovance Biotherapeutics' most important product is generating rapidly growing sales.","fetched_title":"Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? | Nasdaq","final_url":"https://www.nasdaq.com/articles/biotech-stock-best-chance-make-fortune-healthcare","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/biotech-stock-best-chance-make-fortune-healthcare","source_event_id":"evt_8ff4fa0f775a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"74aa5ad3dae62c85","kind":"unusual_volume","published_at":"2026-04-10T16:50:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2024","last year","next couple of years","over the next five years","April 10, 2026"],"entities":[{"asset_class":"equity","name":"Iovance Biotherapeutics","relevance":"high","symbol":"IOVA","type":"company"},{"asset_class":"biotech_product","name":"Amtagvi","relevance":"high","symbol":"","type":"product"},{"asset_class":"biotech_product","name":"lifileucel","relevance":"medium","symbol":"","type":"drug_generic_name"},{"asset_class":"market","name":"NASDAQ","relevance":"low","symbol":"","type":"exchange"}],"event_type":"other","information_gaps":["No unusual trading volume data is provided (baseline volume, current volume, volume ratio vs average, or direction are not stated).","No explicit catalyst tied to the signal type (discovery_unusual_volume_delta) is described; the article\u2019s catalysts are product sales growth, global approvals, and label expansion/clinical trial results.","The article does not confirm whether any volume spike occurred or whether it is unexplained; it is not discussed in the provided text."],"key_facts":["The article states Iovance Biotherapeutics\u2019 most important product is Amtagvi.","The article states Amtagvi sales were $263.5 million in the last fiscal year.","The article states Amtagvi sales were up almost 61% from the previous fiscal year.","The article states Amtagvi was approved in 2024 for advanced melanoma.","The article states Amtagvi is expanding globally, including approval in Canada last year.","The article states the company could receive regulatory approval in various European countries and Australia over the next couple of years (as described by the article).","The article states the company announced positive early results from a pivotal clinical trial of lifileucel in advanced soft-tissue sarcomas (as described by the article).","The article states the company argues there is an opportunity of more than 8,000 patients diagnosed annually in the U.S. and Europe (as described by the article).","The article states Iovance develops tumor-infiltrating lymphocyte (TIL) therapies that are difficult to administer and require dedicated treatment centers.","The article states Amtagvi manufacturing takes about 34 days (as described by the article).","The article states the therapy model makes it challenging to turn a profit due to high price and cost (as described by the article).","The article characterizes the stock as risky and suggests initiating only a small position initially (as described by the article)."],"numeric_claims":[{"label":"Amtagvi sales (last fiscal year, USD millions)","value":"263.5"},{"label":"Amtagvi sales growth (YoY)","value":"almost 61%"},{"label":"Amtagvi manufacturing time (days)","value":"34"},{"label":"Patient opportunity (U.S. and Europe)","value":"more than 8,000"},{"label":"Potential annual sales target by 2030 (USD)","value":"exceed $1 billion"}],"primary_claim":"Iovance Biotherapeutics\u2019 sales for Amtagvi were $263.5 million in the last fiscal year, up almost 61% year over year, and the article suggests potential future growth from global approvals and label expansions.","relevance_score":0.35,"sentiment":"mixed","source_quality":"high","summary":"The article discusses Iovance Biotherapeutics (NASDAQ: IOVA) as a potentially promising but high-risk biotech, citing strong sales growth for its melanoma therapy Amtagvi and possible label expansions. It does not provide any unusual trading volume figures or a volume-vs-average ratio.","topics":["biotech","equity investing","Iovance Biotherapeutics","Amtagvi","lifileucel","melanoma","label expansion","clinical trial","risk factors"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsIovance Biotherapeutics' most important product is generating rapidly growing sales.","tickers":[],"title":"Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?","url":"https://www.fool.com/investing/2026/04/10/is-this-biotech-stock-the-best-chance-to-make-a-fo/"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel